Brief introduction of Zhejiang Jingxin pharmaceutical co., ltd.

Zhejiang Jingxin Pharmaceutical Co., Ltd. is a cross-regional and cross-regional pharmaceutical listed company integrating pharmaceutical research and development, production and sales, and a national key high-tech enterprise. The company has employees, the head office is located in Xinchang, there are preparation production bases in Xinchang, raw material medicine production bases in Shangyu, Jiangxi, marketing centers in Hangzhou, Zhejiang, R&D centers in Zhangjiang High-tech Park in Shanghai, and Chinese medicine production bases in Bayannaoer, Inner Mongolia.

The company's products include chemical preparations, bulk drugs, traditional Chinese medicines and biological preparations, including antibacterial drugs, cardiovascular and cerebrovascular drugs, neuropsychotics and quinolones. The domestic production, sales and market share of raw materials such as levofluoride hydrochloride and cyclopropyl hydrochloride are among the best, and their products sell well in international markets such as Southeast Asia, South Asia, Latin America and Europe. Raw materials and preparations of rosuvastatin calcium have been produced on a large scale.

The company has postdoctoral research center, Zhejiang Enterprise Research Institute and provincial technical center, and cooperates with many national medical research institutions and famous universities. It has strong scientific research and technical strength, and has achieved fruitful research and development results. It owns 7 national key new products and undertakes 7 national torch plan projects, and sertraline hydrochloride is rated as a national biomedical high-tech industry demonstration project.

With the quality concept of "Beijing new drug, carefully manufactured", the company passed the German GMP certification for the first time in 2006, passed the new GMP certification on 201,and passed the German (EU) GMP re-certification on 20 12. Simvastatin and ciprofloxacin hydrochloride also obtained COS certificates, ciprofloxacin hydrochloride also passed EDQM on-site inspection and obtained French GMP certificates.

In 2008, simvastatin tablets were exported to the UK for the first time, which opened the export of finished chemicals from China to the UK high-end market. In 2009, the company achieved the goal of exporting finished drugs to Germany. In 20 12, the export of pharmaceutical preparations further explored the European market, and the growth momentum was rapid. The company was also listed as "excellent enterprise brand of China pharmaceutical industry" and "leading enterprise of pharmaceutical internationalization in China".

With the core business philosophy of "building an excellent enterprise and building a new brand in Beijing", the company's comprehensive economic benefits have been rapidly improved. Since 20 10, the company has been listed among the top 100 chemical and pharmaceutical enterprises in China, and has successively won the titles of "AAA enterprise with abiding by contracts and keeping credit in Zhejiang province", "AAA enterprise with tax credit rating in Zhejiang province", "Zhejiang patent demonstration enterprise" and "outstanding innovative enterprise in Zhejiang province".